- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Blincyto® | bscCD19xCD3 | MEDI-538 | MT-103 | MT103 
blinatumomab is an approved drug (FDA (2014), EMA (2015))
Compound class: Antibody
Comment: Blinatumomab is a monoclonal antibody with anti-cancer effects. Its mechanism of action classifies this antibody as a member of the bi-specific T-cell engager (BiTE®) group of engineered antibodies. It was the first biologic of this class to gain clinical approval.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|The development of blinatumomab is covered by patent US7635472 , based on peptide sequence matches of the two antigen-binding variable heavy chains regions of blinatumomab. In this patent specificity and efficacy of blinatumomab binding was determined by FACS analysis and ELISA. However, the specific clone producing blinatumomab is not reported, nor are binding affinity values for antibody-antigen interactions|
|Selectivity at other protein targets|
|Key to terms and symbols||Click column headers to sort|